What Signadori Bio does

Signadori Bio is a preclinical-stage biopharmaceutical company developing in vivo monocyte immunotherapy for solid tumors. Founded in March 2025 through a strategic partnership between Sofinnova Partners and Institut Gustave Roussy, the company is headquartered in Paris, France, operates with 1-10 employees, and is privately held with no products on market. Its core focus is treating solid tumors resistant to existing immunotherapies and autologous cell therapies by engineering monocytes directly in the patient to enhance anti-tumor immunity.

The company's proprietary platform is built on p21 (CDKN1A) biology, which the scientific co-founders identified as a master regulator of myeloid anti-tumor functions (first patented in 2020, published in Nature Communications in 2022). p21-Engineered Monocytes are designed to circulate systemically, leverage natural tumor tropism to infiltrate the tumor microenvironment, and differentiate into macrophages with enhanced phagocytic activity and dendritic cells capable of presenting tumor-associated antigens and recruiting adaptive immune effectors. The pipeline comprises four programs (SiB-2101 lead; SiB-2111; SiB-2121; SiB-2191 target-independent), with SiB-2101 candidate nomination expected in 1Q27 and first-in-human trial initiation expected in 4Q28.

The business model is pre-revenue and funded entirely by venture capital (cumulative €11.1M raised across seed rounds from Sofinnova Partners, Invivo Partners, and Taiho Ventures). Future revenue is expected to derive from licensing/royalty agreements, milestone payments, and potential future product sales. The go-to-market motion is event-driven, combining investor/partnering conference presentations (ChinaBio Partnering Forum in Shanghai, 26th Bio€quity Europe in Prague) with high-touch enterprise BD outreach to biopharma collaborators. A strategic partnership with eXmoor Pharma supports technology translation and GMP-compliant manufacturing readiness.

Name

Signadori Bio

Legal name

Signadori Bio SAS

Website

https://signadoribio.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

Signadori Bio is a preclinical-stage French biopharmaceutical company developing an off-the-shelf in vivo monocyte immunotherapy platform based on p21 (CDKN1A) biology, with a four-program pipeline (lead: SiB-2101) targeting solid tumors resistant to current immunotherapies.

Ownership category

akta.pro rank

Product category

Cancer Cell Therapy / Immuno-Oncology

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)

akta.pro secondary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• Cell therapy immunotherapy
• Immuno-oncology platform
• Monocyte engineering therapy
• Solid tumor treatment
• Preclinical biopharmaceuticals

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Others

Revenue model

1. Pre-revenue / no commercial revenue: Signadori Bio is a preclinical-stage biopharmaceutical company with no products on the market and therefore no recurring or transactional revenue. Operations are funded by venture capital (seed extension financing bringing total to €11.1 million). Future revenue would derive from licensing/royalties, milestone payments from partnerships, or potential future product sales if candidates progress to market.

Go-to-market motion2 records

Marketing channels5 records

Core offering

Signadori Bio is a preclinical-stage biopharmaceutical company developing a proprietary in vivo monocyte engineering platform based on p21 (CDKN1A) biology. The platform reprograms myeloid cells directly in the patient to enhance anti-tumor immunity against solid tumors, underpinning a pipeline of off-the-shelf gene-modified monocyte immunotherapy candidates (SiB-2101 lead program plus three earlier-stage programs). The company currently has no products on the market and operates via R&D collaborations, strategic alliances, and venture funding.

Product overview

Signadori Bio is a preclinical-stage biopharmaceutical company developing a single, unified in vivo monocyte engineering platform — rather than a platform-plus-modules architecture — that underpins its pipeline of off-the-shelf p21-Engineered Monocyte Therapy candidates for solid tumour immunotherapy. The platform is built around the p21 protein (CDKN1A), identified by the company's scientific co-founders as a master regulator of myeloid anti-tumor functions, and comprises four pipeline programs that all share the same p21-engineered monocyte modality: the lead program SiB-2101 (Target 1), SiB-2111 (Target 2), SiB-2121 (Target 3), and the target-independent SiB-2191. SiB-2101 is the most advanced candidate, while SiB-2111, SiB-2121, and SiB-2191 are earlier-stage programs leveraging the same p21 reprogramming platform.

Differentiator

Problem solved

Functional benefit

Products and services

• SiB-2101 Lead pipeline program: a p21-Engineered Monocyte Therapy targeting Target 1 in solid tumors. The most advanced candidate in Signadori Bio's pipeline, currently in preclinical validation, with candidate nomination expected in Q1 2027 and first-in-human trial initiation expected in Q4 2028.
• SiB-2111 p21-Engineered Monocyte Therapy program targeting Target 2, currently in discovery/preclinical stages.
• SiB-2121 p21-Engineered Monocyte Therapy program targeting Target 3, currently in discovery/preclinical stages.
• SiB-2191 Target-Independent p21-Engineered Monocyte Therapy program, currently in discovery/preclinical stages, designed to leverage the p21 myeloid reprogramming platform independent of a specific target.

Quantifiable outcome

• Candidate nomination for lead program SiB-2101 expected 1Q27; first-in-human trial initiation expected 4Q28
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators5 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Carisma Therapeutics: Clinical-stage biotech developing engineered macrophage cell therapies (CAR-Macrophages) for solid tumors. Most directly comparable to Signadori Bio given both are pursuing myeloid-directed cell therapy approaches for solid tumor indications, with Carisma more advanced in the clinic.
• Myeloid Therapeutics: Clinical-stage biotech developing myeloid cell therapies including in vivo reprogramming of myeloid cells. Closest direct peer to Signadori Bio given parallel focus on engineering monocytes/macrophages to fight cancer using novel myeloid biology.
• Arsenal Bio: Clinical-stage cell therapy company engineering T cells and other immune cells for solid tumors. Comparable to Signadori in targeting the solid tumor microenvironment with engineered cell therapy approaches, though focused on T-cell rather than myeloid engineering.
• Century Therapeutics: Clinical-stage iPSC-derived engineered cell therapy company developing allogeneic therapies for solid tumors. Comparable to Signadori in pursuing off-the-shelf, engineered cell therapy approaches for solid tumors, with broader modality coverage.
• Fate Therapeutics: Clinical-stage biotech developing iPSC-derived NK and T-cell therapies for cancer. Comparable to Signadori in pursuing off-the-shelf engineered cell therapy platforms, though with NK/T-cell focus rather than myeloid cells.
• Nkarta Therapeutics: Clinical-stage cell therapy company engineering NK cells for cancer. Comparable to Signadori in the broader engineered cell therapy space, though Signadori's myeloid focus is differentiated from NK cell approaches.
• Cellectis: Clinical-stage French biotech pioneering allogeneic CAR-T cell therapies using gene editing. Comparable to Signadori as a French-based gene-edited cell therapy company, though Cellectis focuses on T-cell rather than myeloid engineering.

Emerging players

• Resolution Therapeutics: Clinical-stage European biotech developing macrophage cell therapies for inflammatory and fibrotic diseases, with emerging oncology applications. Comparable in macrophage engineering approach, though focused on resolution of inflammation rather than solid tumor immunotherapy.

Broad incumbents

• Gilead Sciences (Kite Pharma): Large biopharmaceutical company with a leading cell therapy franchise (Yescarta, Tecartus) through Kite Pharma. Broad incumbent in cell therapy, indirectly comparable to Signadori as a potential strategic acquirer/partner for differentiated solid tumor approaches.
• Bristol-Myers Squibb: Large biopharmaceutical company with leading CAR-T cell therapy franchise (Breyanzi, Abecma) and a strong immuno-oncology pipeline. Broad incumbent potentially interested in complementary myeloid-based solid tumor platforms, comparable as a potential strategic partner.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/signadori-bio

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Signadori Bio